BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 06, 2007
 |  BioCentury  |  Regulation

Induction outcomes

Induction outcomes

Induction outcomes
Data from two Phase III induction studies of Tysabri in moderate to severe Crohn's disease. In the intent-to-treat population in study CD301, clinical response and remission at 10 weeks favored Tysabri, but the results were not significant. However, both endpoints were significant versus placebo in a...

Read the full 254 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >